Ultrasonographic fatty liver indicator detects mild steatosis and correlates with metabolic/histological parameters in various liver diseases

Metabolism: Clinical and Experimental

Volumn 72, Issue , 2017, Pages 57-65

  Ballestri, Stefano ^a   Nascimbeni, Fabio ^b,c   Baldelli, Enrica ^c   Marrazzo, Alessandra ^c   Romagnoli, Dante ^b   Targher, Giovanni ^d   Lonardo, Amedeo ^b  

^a AUSL Modena   (Italy)

^b Nuovo Ospedale S Agostino   (Italy)

^c UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^d UNIVERSITY HOSPITAL OF VERONA   (Italy)

Author keywords

Accuracy; Liver biopsy; Liver enzymes; Metabolic syndrome

Indexed keywords

ADULT; ARTICLE; BODY MASS; CONTROLLED STUDY; ECHOGRAPHY; FATTY LIVER; FEMALE; HEPATITIS B; HEPATITIS C; HUMAN; HUMAN TISSUE; INSULIN RESISTANCE; LIVER BIOPSY; LIVER DISEASE; MAJOR CLINICAL STUDY; MALE; METABOLIC PARAMETERS; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; ULTRASONOGRAPHIC FATTY LIVER INDICATOR; WAIST CIRCUMFERENCE; COMPLICATION; DIAGNOSTIC IMAGING; METABOLISM; METABOLOMICS; MIDDLE AGED; NONALCOHOLIC FATTY LIVER; PROCEDURES; SEVERITY OF ILLNESS INDEX; STATISTICS AND NUMERICAL DATA; VIROLOGY;

ADULT; FATTY LIVER; FEMALE; HEPATITIS B; HEPATITIS C; HUMANS; INSULIN RESISTANCE; LIVER DISEASES; MALE; METABOLOMICS; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; ULTRASONOGRAPHY; WAIST CIRCUMFERENCE;

EID: 85018333772     PISSN: 00260495     EISSN: 15328600     Source Type: Journal    
DOI: 10.1016/j.metabol.2017.04.003     Document Type: Article

References (42)

1. [1] Loria, P., Marchesini, G., Nascimbeni, F., Ballestri, S., Maurantonio, M., Carubbi, F., et al. Cardiovascular risk, lipidemic phenotype and steatosis. A comparative analysis of cirrhotic and non-cirrhotic liver disease due to varying etiology. Atherosclerosis 232 (2014), 99–109.
2. [2] Non-alcoholic fatty liver disease (NAFLD) study group, Lonardo, A., Bellentani, S., Argo, C.K., Ballestri, S., Byrne, C.D., Caldwell, S.H., et al. Epidemiological modifiers of non-alcoholic fatty liver disease: focus on high-risk groups. Dig Liver Dis 47 (2015), 997–1006.
3. [3] Fazel, Y., Koenig, A.B., Sayiner, M., Goodman, Z.D., Younossi, Z.M., Epidemiology and natural history of non-alcoholic fatty liver disease. Metabolism 65 (2016), 1017–1025.
4. [4] Ballestri, S., Zona, S., Targher, G., Romagnoli, D., Baldelli, E., Nascimbeni, F., et al. Nonalcoholic fatty liver disease is associated with an almost two-fold increased risk of incident type 2 diabetes and metabolic syndrome. Evidence from a systematic review and meta-analysis. J Gastroenterol Hepatol 31 (2016), 936–944.
5. [5] Ballestri, S., Nascimbeni, F., Romagnoli, D., Lonardo, A., The independent predictors of non-alcoholic steatohepatitis and its individual histological features: insulin resistance, serum uric acid, metabolic syndrome, alanine aminotransferase and serum total cholesterol are a clue to pathogenesis and candidate targets for treatment. Hepatol Res 46 (2016), 1074–1087.
6. [6] Katsiki, N., Mikhailidis, D.P., Mantzoros, C.S., Non-alcoholic fatty liver disease and dyslipidemia: an update. Metabolism 65 (2016), 1109–1123.
7. [7] Lonardo, A., Adinolfi, L.E., Restivo, L., Ballestri, S., Romagnoli, D., Baldelli, E., et al. Pathogenesis and significance of hepatitis C virus steatosis: an update on survival strategy of a successful pathogen. World J Gastroenterol 20 (2014), 7089–7103.
8. [8] Chalasani, N., Wilson, L., Kleiner, D.E., Cummings, O.W., Brunt, E.M., Unalp, A., NASH Clinical Research Network. Relationship of steatosis grade and zonal location to histological features of steatohepatitis in adult patients with non-alcoholic fatty liver disease. J Hepatol 48 (2008), 829–834.
9. [9] Ballestri, S., Romagnoli, D., Nascimbeni, F., Francica, G., Lonardo, A., Role of ultrasound in the diagnosis and treatment of nonalcoholic fatty liver disease and its complications. Expert Rev Gastroenterol Hepatol 9 (2015), 603–627.
10. [10] Alkhouri, N., Feldstein, A.E., Noninvasive diagnosis of nonalcoholic fatty liver disease: are we there yet?. Metabolism 65 (2016), 1087–1954.
11. [11] Saadeh, S., Younossi, Z.M., Remer, E.M., Gramlich, T., Ong, J.P., Hurley, M., et al. The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology 123 (2002), 745–750.
12. [12] Dasarathy, S., Dasarathy, J., Khiyami, A., Joseph, R., Lopez, R., McCullough, A.J., Validity of real time ultrasound in the diagnosis of hepatic steatosis: a prospective study. J Hepatol 51 (2009), 1061–1067.
13. [13] Bril, F., Ortiz-Lopez, C., Lomonaco, R., Orsak, B., Freckleton, M., Chintapalli, K., et al. Clinical value of liver ultrasound for the diagnosis of nonalcoholic fatty liver disease in overweight and obese patients. Liver Int 35 (2015), 2139–2146.
14. [14] Hamaguchi, M., Kojima, T., Itoh, Y., Harano, Y., Fujii, K., Nakajima, T., et al. The severity of ultrasonographic findings in nonalcoholic fatty liver disease reflects the metabolic syndrome and visceral fat accumulation. Am J Gastroenterol 102 (2007), 2708–2715.
15. [15] Liang, R.J., Wang, H.H., Lee, W.J., Liew, P.L., Lin, J.T., Wu, M.S., Diagnostic value of ultrasonographic examination for nonalcoholic steatohepatitis in morbidly obese patients undergoing laparoscopic bariatric surgery. Obes Surg 17 (2007), 45–56.
16. [16] Ballestri, S., Lonardo, A., Romagnoli, D., Carulli, L., Losi, L., Day, C.P., et al. Ultrasonographic fatty liver indicator, a novel score which rules out NASH and is correlated with metabolic parameters in NAFLD. Liver Int 32 (2012), 1242–1252.
17. [17] Morisco, F., Pagliaro, L., Caporaso, N., Bianco, E., Sagliocca, L., Fargion, S., et al. Consensus recommendations for managing asymptomatic persistent non-virus non-alcohol related elevation of aminotransferase levels: suggestions for diagnostic procedures and monitoring. Dig Liver Dis 40 (2008), 585–598.
18. [18] Levey, A.S., Bosch, J.P., Lewis, J.B., Greene, T., Rogers, N., Roth, D., Modification of Diet in Renal Disease Study Group. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Ann Intern Med 130 (1999), 461–470.
19. [19] Matthews, D.R., Hosker, J.P., Rudenski, A.S., Naylor, B.A., Treacher, D.F., Turner, R.C., Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28 (1985), 412–419.
20. [20] Expert Committee on the Diagnosis and Classification of Diabetes Mellitus, American Diabetes Association: clinical practice recommendations. Diabetes Care 25 (2002), S1–S147.
21. [21] Mancia, G., Fagard, R., Narkiewicz, K., Redon, J., Zanchetti, A., Böhm, M., et al. Guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 34 (2013), 2159–2219.
22. [22] Alberti, K.G., Eckel, R.H., Grundy, S.M., Zimmet, P.Z., Cleeman, J.I., Donato, K.A., et al. Harmonizing the metabolic syndrome: a joint interimstatement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 120 (2009), 1640–1645.
23. [23] Ballestri, S., Nascimbeni, F., Romagnoli, D., Lonardo, A., Do ultrasonographic semiquantitative indices predict histological changes in NASH irrespective of steatosis extent?. Liver Int 35 (2015), 2340–2341.
24. [24] Brunt, E.M., Janney, C.G., Di Bisceglie, A.M., Neuschwander-Tetri, B.A., Bacon, B.R., Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol 94 (1999), 2467–2474.
25. [25] Kleiner, D.E., Brunt, E.M., Van Natta, M., Behling, C., Contos, M.J., Cummings, O.W., et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 41 (2005), 1313–1321.
26. [26] Scheuer, P.J., Classification of chronic viral hepatitis: a need for reassessment. J Hepatol 13 (1991), 372–374.
27. [27] Ishak, K., Baptista, A., Bianchi, L., Callea, F., De Groote, J., Gudat, F., et al. Histological grading and staging of chronic hepatitis. J Hepatol 22 (1995), 696–699.
28. [28] Bedogni, G., Bellentani, S., Miglioli, L., Masutti, F., Passalacqua, M., Castiglione, A., et al. The fatty liver index: a simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterol, 6, 2006, 33.
29. [29] Cuthbertson, D.J., Weickert, M.O., Lythgoe, D., Sprung, V.S., Dobson, R., Shoajee-Moradie, F., et al. External validation of the fatty liver index and lipid accumulation product indices, using 1H-magnetic resonance spectroscopy, to identify hepatic steatosis in healthy controls and obese, insulin-resistant individuals. Eur J Endocrinol 171 (2014), 561–569.
30. [30] Hernaez, R., Lazo, M., Bonekamp, S., Kamel, I., Brancati, F.L., Guallar, E., et al. Diagnostic accuracy and reliability of ultrasonography for the detection of fatty liver: a meta-analysis. Hepatology 54 (2011), 1082–1090.
31. [31] Palmentieri, B., de Sio, I., La Mura, V., Masarone, M., Vecchione, R., Bruno, S., et al. The role of bright liver echo pattern on ultrasound B-mode examination in the diagnosis of liver steatosis. Dig Liver Dis 38 (2006), 485–489.
32. [32] Soresi, M., Giannitrapani, L., Florena, A.M., La Spada, E., Di Gesaro, V., Rappa, F., et al. Reliability of the bright liver echo pattern in diagnosing steatosis in patients with cryptogenic and HCV-related hypertransaminasaemia. Clin Radiol 64 (2009), 1181–1187.
33. [33] Hepburn, M.J., Vos, J.A., Fillman, E.P., Lawitz, E.J., The accuracy of the report of hepatic steatosis on ultrasonography in patients infected with hepatitis C in a clinical setting: a retrospective observational study. BMC Gastroenterol, 5, 2005, 14.
34. [34] Perez, N.E., Siddiqui, F.A., Mutchnick, M.G., Dhar, R., Tobi, M., Ullah, N., et al. Ultrasound diagnosis of fatty liver in patients with chronic liver disease: a retrospective observational study. J Clin Gastroenterol 41 (2007), 624–629.
35. [35] Chen, C.H., Lin, S.T., Yang, C.C., Yeh, Y.H., Kuo, C.L., Nien, C.K., The accuracy of sonography in predicting steatosis and fibrosis in chronic hepatitis C. Dig Dis Sci 53 (2008), 1699–1706.
36. [36] Loy, M., Serra, G., Chessa, L., The prevalence of bright liver echo pattern in patients with chronic hepatitis C: correlation with steatosis and fibrosis. J Ultrasound 19 (2014), 91–98.
37. [37] Macaluso, F.S., Maida, M., Cammà, C., Cabibi, D., Alessi, N., Cabibbo, G., et al. Body mass index and liver stiffness affect accuracy of ultrasonography in detecting steatosis in patients with chronic hepatitis C virus genotype 1 infection. Clin Gastroenterol Hepatol 12 (2014), 878–884.
38. [38] Mathiesen, U.L., Franzen, L.E., Aselius, H., Resjo, M., Jacobsson, L., Foberg, U., et al. Increased liver echogenicity at ultrasound examination reflects degree of steatosis but not of fibrosis in asymptomatic patients with mild/moderate abnormalities of liver transaminases. Dig Liver Dis 34 (2002), 516–522.
39. [39] Fedchuk, L., Nascimbeni, F., Pais, R., Charlotte, F., Housset, C., Ratziu, V., et al. Performance and limitations of steatosis biomarkers in patients with nonalcoholic fatty liver disease. Aliment Pharmacol Ther 40 (2014), 1209–1222.
40. [40] Liao, Y.Y., Yang, K.C., Lee, M.J., Huang, K.C., Chen, J.D., Yeh, C.K., Multifeature analysis of an ultrasound quantitative diagnostic index for classifying nonalcoholic fatty liver disease. Sci Rep, 6, 2016, 35083.
41. [41] Targher, G., Byrne, C.D., Lonardo, A., Zoppini, G., Barbui, C., Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: a meta-analysis. J Hepatol 65 (2016), 589–600.
42. [42] Lonardo, A., Sookoian, S., Pirola, C.J., Targher, G., Non-alcoholic fatty liver disease and risk of cardiovascular disease. Metabolism 65 (2016), 1136–1150.